Prognostic factors for the survival in infiltrating bladder urothelial tumor: Retrospective study of 158 patients treated by radical cystectomy;FACTEURS PRONOSTIQUES DE SURVIE DANS LES CARCINOMES UROTHELIAUX INFILTRANTS DE VESSIE. ETUDE RETROSPECTIVE DE 158 CAS TRAITES PAR CYSTECTOMIE RADICALE

Bulletin du Cancer

Volumn 83, Issue 2, 1996, Pages 139-146

  Thieblemont, C ^a   Fendler, J P ^b   Trillet Lenoir, V ^a   Petris, C ^b   Chauvin, F ^c   Brunat Mentigny, M ^c   Devaux, Y ^a   Devonec, M ^b   Gerard J P ^a   Perrin, P ^b  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Hopital de l'Antiquaille   (France)

^c CENTRE LÉON BÉRARD   (France)

Author keywords

chemotherapy; infiltrating bladder cancer; radiotherapy; survival; transitional cell carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER STAGING; CELL INVASION; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL;

ADULT; AGED; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 9044229138     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Azab M, Theodore C, Cukier J, Beurton D, Gilles E, Droz JP. Chimiothérapie adjuvante par adriamycine et cisplatine dans les cancers infiltrants de la vessie. Étude prospective sur 49 cas. J Urol 1989;95:459-63
2. Boutan-Laroze A, Mahjoudi M, Droz JP. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur J Cancer 1991;27:1690-4
3. Coombs LM, Pigott DA, Eydmann ME, Proctor AJ, Knowles MA. Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma. Br J Cancer 1993;67:578-84
4. Cox DR. Regressions models and life tables (with discussion). J R Stat Soc Ser 1972;B34:187-220
5. Droller MJ. The controversial role of radiation therapy as adjunctive treatment of bladder cancer. J Urol 1983;129: 897-903
6. Esrig D, Elmajian D, Grshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;321:1259-64
7. Greven KM, Spera JA, Soltn LJ, Morgan T, Hanks GE. Local recurrence after cystectomy alone for bladder carcinoma. Cancer 1992;69:2767-70
8. Kaplan EL, Meier P. Non parametric estimation from uncomplete observations. J Am Stat Assoc 1958;53:457-81
9. Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 1993;29:749-53
10. Loehrer PJ, Elson P, Dreicer R et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994;12:483-8
11. Logothetis CJ, Dexeus FH, Finn L et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8:1050-5
12. Lopez-Beltran A, Croghan GA, Croghan I, Huben RP, Mettlin C, Gaeta JF. Pronostic factors in survival of bladder cancer. Cancer 1992;70:799-807
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
14. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F et al. Neoadjuvant cysplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995;153: 964-73
15. Moore MJ, Iscoe N, Tannock I. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993;150:1131-4
16. Miller LS. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 1987;39:973-6
17. Miller LS, Freiha FS, Reese JH, Ozen H, Torti FM. Cisplatin, methotrexate and vinblastine plus surgical restaging for patients with advanced transitional cell carcinoma of the urothelium. J Urol 1993;150:65-9
18. Natale RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich M, Braun DW. Methotrexate: an active drug in bladder cancer. Cancer 1981;47:1246-50
19. Raghavan D, Shipley WU, Garnick MB, Russel PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990;322:1129-38
20. Scher HI, Norton L. Chemotherapy for urothelial tract malignancies: breaking the dedlock. Sem Surg Oncol 1992;8: 316-41
21. Scher HI, Geller NL, Curley T, Tao Y. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 1993;11: 400-7
22. Schultz PK, Herr HW, Zhang ZF et al. Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994;12:1394-1401
23. Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection can make a difference. J Urol 1982;128:34-6
24. Skinner DG, Daniels JR, Russel CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145:459-67
25. Smith PH. Chemotherapy of bladder cancer: a review. Cancer Treat Rep 1981;65:165-73
26. Smith JA, Whitmore WF. Regional lymph node metastasis from bladder cancer. J Urol 1981;126:591-3
27. Splinter TAW, Scher HI, Denis L et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 1992;147:606-8
28. Sternberg CN, Yagoda A, Scher H et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 1989;64:2448-58
29. Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1, and pN2): improved survival after radical cystectomy and adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;142:302-7
30. Stökle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 1995;153:47-52
31. Uchida T, Wada C, Ishida H, Wang C, Egawa S, Yokoyama E et al. p53 mutations and prognosis in bladder tumors. J Urol 1995;153:1097-1104
32. Whitmore WF, Grabstald H, McKenzie AR. Preoperative irradiation with cystectomy in the management of bladder cancer. Am J Roentgenol 1968;102:570-6
33. Whitmore WF, Batata MA, Hilaris BS et al. A comparative study of two preoperative radiation regimens with bladder cancer. Cancer 1977;40:1077-1981
34. Yagoda A, Watson RC, Gonzales-Vitale JC, Grabsteld H, Whitmore WF. Cis-dichlorodiamine platinum (II) in advanced bladder cancer. Cancer Treat Rep 1976;60:917-23
35. Ye DW, Zhen JF, Qian SX, Ma YJ. Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. Urol Res 1993;21:39-43